UK perspective on the changing landscape of non-invasive cardiac testing

Alex Asher, Rahul Ghelani, George Thornton, Krishnaraj Rathod, Daniel Jones, Andrew Wragg, Adam Timmis

ABSTRACT

Objective To document UK rates of exercise treadmill testing, functional stress testing and CT coronary angiography (CTCA). Specific aims were to determine how rates have changed in the context of changing guideline recommendations within the UK and to identify regional inequalities in the utilisation of testing modalities. Secondary objectives were to compare these trends with national data on revascularisation.

Methods 159 acute National Health Service trusts were served Freedom of Information (FOI) requests to provide total numbers of CTCA and functional imaging tests for each financial year from 2011–2012 to 2016–2017.

Results The FOI requests yielded data from 88% of Trusts, increasing from 81.9% in 2011–2012 to 92.1% in 2016–2017. Exercise treadmill tests (ETTs) were performed by over 97% of Trusts. ETT was the most commonly performed diagnostic test in the UK across the study period despite declining by 8.4%. Utilisation of non-invasive stress imaging tests increased by 80.9% during the same period. Myocardial perfusion scintigraphy and stress echocardiography increased by 25.8% and 73.9%, respectively. The 268% increase in CTCA scans was yet greater. Trends in test utilisation during the study period showed important regional differences between devolved nations. Comparably, only small changes in rates of invasive coronary angiography and revascularisation have been reported during the study period.

Conclusion Non-invasive imaging in UK Trusts has increased substantially since 2010 with only a small decline in use of the ETT and minimal changes in rates of invasive coronary angiography and revascularisation in the same time period.

INTRODUCTION

The last 10 years have seen major shifts in UK guideline recommendations for non-invasive cardiac testing of patients with undiagnosed chest pain. Historically exercise treadmill testing (ETT) was recommended as a diagnostic test in patients with suspected coronary artery disease in the UK. In 2010 the National Institute of Care Excellence (NICE) changed this by recommending that the (ETT) should no longer be used for this purpose due to poor diagnostic accuracy and instead recommended use of non-invasive imaging testing for more accurate diagnosis of coronary artery disease. A further 6 years later in 2016 the guideline was further nuanced with CT coronary angiography (CTCA) becoming the favoured investigation for all patients with new atypical or typical chest pain and with perfusion and stress imaging preferred for patients with a known diagnosis of coronary artery disease or unsuitable for CTCA. European guidelines for management of chronic coronary syndromes largely mirror these recommendations with an emphasis on use of non-invasive testing prior to revascularisation.

While recommendations for ETT in patients with undiagnosed chest pain are now diminished these tests continue to have an important role for patients with other cardiac disorders. Equally since the 2010 NICE guideline the scope for use of non-invasive imaging tests has widened beyond just stable coronary artery disease. Cardiac
CT are important tools in assessing aortic stenosis, masses or congenital heart diseases. Stress echocardiography can be a helpful discriminator in ‘low-flow’ aortic stenosis. Cardiac MRI or myocardial perfusion scintigraphy (MPS) are used to guide revascularisation decisions using both perfusion and viability assessments.

With expanding indications for these tests, it is not known how their utilisation has changed within the UK in recent years. It is equally unclear how this in turn has impacted rates of invasive coronary angiography (ICA) and revascularisation. These questions are important not only for benchmarking purposes but also for identifying efficiency of resources utilisation at a time of increasing constraints. In the present study we have addressed this knowledge gap by documenting for the first-time rates of non-invasive testing across UK cardiac centres. Specific aims were to determine how rates of testing have changed since 2010 and to identify regional inequalities in the utilisation of testing modalities.

METHODS
159 acute National Health Service (NHS) trusts and health boards providing adult cardiology services in England, Scotland, Wales and Northern Ireland were identified from each nation’s NHS website (www.nhs.uk, https://www.scot.nhs.uk, http://online.hscni.net, https://www.wales.nhs.uk). Each trust or health board was asked to provide information under the UK’s Freedom of Information (FOI) act 1998. Under the FOI act all public bodies must respond, if feasible within 20 working days, to all requests for information that do not meet exclusions from the act. Each trust was sent five FOI requests via either email or an online request system, requesting that they provide the total numbers of non-invasive cardiac tests, both anatomical (CTCA) and functional (ETT, stress perfusion cardiac MRI, myocardial stress perfusion and stress echocardiography) for each financial year from 2011–2012 to 2016–2017. No information was requested regarding indication for the tests performed due to exclusions of the FOI act precluding this. An individual information request was made for each cardiac investigation and all requests were made within the period of 1 August 2018 to 31 December 2018. Trusts not responding within 20 working days were chased for response via email up to three times before data were presumed to be missing (figure 1). Clarification or rechecking of data was requested from the Trusts using SNOMED codes if incorrect or anomalous data was suspected (ie, data including non-stress cardiac MRI, inconsistency in numbers reported year to year or number of tests reported well above expected levels). The exact FOI requests made for each test can be found in online supplementary file 1. National rates of ICA and revascularisation were obtained from the British Cardiovascular Interventional Society and the Society for Cardithoracic Surgery registries.

This is a descriptive study and no formal statistical analysis has been performed.

Results are displayed as both total number of tests and tests per 100 000 of population per year in the UK. Tests are also represented as mean tests per NHS trust per year to account for unreported data from NHS trusts. Data for

**Figure 1** Methods flowchart. FOI, Freedom of Information; NHS, National Health Service.
Coronary artery disease

Table 1  Total number and percentages of UK National Health Service trusts that responded to Freedom of Information requests performing individual tests between 2011–2012 and 2016–2017

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CTCA</td>
<td>77 (56.6%)</td>
<td>84 (59.2%)</td>
<td>100 (66.7%)</td>
<td>106 (70.2%)</td>
<td>111 (73.5%)</td>
<td>116 (74.4%)</td>
</tr>
<tr>
<td>ETT</td>
<td>122 (97.6%)</td>
<td>129 (97.0%)</td>
<td>132 (97.8%)</td>
<td>135 (97.8%)</td>
<td>138 (97.9%)</td>
<td>141 (97.9%)</td>
</tr>
<tr>
<td>SE</td>
<td>73 (60.3%)</td>
<td>85 (65.4%)</td>
<td>98 (73.1%)</td>
<td>102 (73.4%)</td>
<td>109 (76.8%)</td>
<td>115 (80.4%)</td>
</tr>
<tr>
<td>CMR</td>
<td>27 (19.6%)</td>
<td>35 (24.8%)</td>
<td>39 (27.3%)</td>
<td>40 (27.6%)</td>
<td>44 (30.1%)</td>
<td>46 (31.5%)</td>
</tr>
<tr>
<td>MPS</td>
<td>79 (60.3%)</td>
<td>82 (61.7%)</td>
<td>88 (63.3%)</td>
<td>89 (62.7%)</td>
<td>92 (64.3%)</td>
<td>91 (63.6%)</td>
</tr>
</tbody>
</table>

CMR, cardiac stress/perfusion MRI; CTCA, CT coronary angiography; ETT, exercise treadmill testing; MPS, myocardial perfusion scintigraphy; SE, stress echocardiography.

Table 2  Test utilisation in UK National Health Service trusts between 2011–2012 and 2016–2017

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CTCA</td>
<td>141.7</td>
<td>192.9</td>
<td>240.9</td>
<td>280.8</td>
<td>322.1</td>
<td>454.7</td>
</tr>
<tr>
<td>ETT</td>
<td>1088.2</td>
<td>1007.6</td>
<td>1003.1</td>
<td>964.6</td>
<td>907.7</td>
<td>865.6</td>
</tr>
<tr>
<td>SE</td>
<td>292.0</td>
<td>322.0</td>
<td>349.7</td>
<td>374.1</td>
<td>402.4</td>
<td>429.8</td>
</tr>
<tr>
<td>CMR</td>
<td>44.3</td>
<td>56.4</td>
<td>72.8</td>
<td>82.0</td>
<td>94.9</td>
<td>107.1</td>
</tr>
<tr>
<td>MPS</td>
<td>530.3</td>
<td>573.7</td>
<td>636.8</td>
<td>628.3</td>
<td>613.8</td>
<td>611.4</td>
</tr>
</tbody>
</table>

Data are the total numbers of tests performed each year.

RESULTS

Data completeness

A total of 795 FOI requests were made between 1 August 2018 and 30 October 2018. For all diagnostic tests the requests yielded data from 88% of UK NHS Trusts, the yield increasing from 81.9% in 2011–2012% to 92.1% in 2016–2017 (see online supplementary file 1).

Exercise treadmill test (ETT)

ETTs were performed by over 97% of reporting Trusts during the study period (table 1). In 2011–2012 the ETT was the most commonly performed diagnostic test when 136 030 (215.3 per 100 000) were performed across the UK (table 2). Thereafter total numbers declined gradually, as non-invasive imaging tests came to be used more commonly (see figures 2 and 3 and). By 2016–2017 the total number of ETTs performed in the UK had fallen by 8.4% to 124647 (189.9 tests per 100 000, 11.8% decrease), with non-invasive imaging now predominantly used. The data, normalised to those Trusts that supplied ETT information (table 3), showed a similar pattern with a 20.5% decrease in the mean number of ETTs per reporting Trust.

Non-invasive imaging tests

Numbers of non-invasive imaging tests increased steeply during the study period, rising by 80.9% from 130 180 in 2011–2012 (206 tests per 100 000) to 235 447 in 2016–2017 (358.7 tests per 100 000). By 2012–2013, numbers had exceeded numbers of ETTs (table 1).

Functional imaging

MPS was offered by 60.3% of reporting Trusts in 2011–2012 with little change during the study period (table 1). It was the most commonly utilised functional imaging test with the total number of scans increasing by 25.8% during the study period, from 69 463 in 2011–2012 (109.9 tests per 100 000) to a peak of 89 224 in 2014–2015 (138.1 tests per 100 000), declining slightly the next 2 years.

Stress echo imaging was offered by 60.3% of reporting Trusts in 2011–2012, increasing to 80.4% in 2016–2017 (table 1). The number of studies in 2011–2012 was 35 338 (55.9 tests per 100 000) but utilisation increased by 73.9% thereafter, peaking at 61 458 in 2016–2017 (93.6 tests per 100 000), only 30% lower than the number of MPS scans.
Cardiac stress MRI was offered by only 19.6% of reporting Trusts in 2011–2012, increasing to 31.5% in 2016–2017 (table 1). The number of scans was consistently lower compared with other imaging tests but increased by 155.9% during the study period from 6109 (9.7 tests per 100 000) in 2011–2012 to 15 634 (23.8 tests per 100 000) in 2016–2017. The data normalised to those Trusts that supplied functional imaging information (table 3) confirmed MPS as the most widely used test per Trust and showed similar patterns of increasing imaging activity, most marked for cardiac stress MRI.

CT coronary angiography
CTCAs were offered by 56.0% of reporting Trusts in 2011–2012, increasing to 74.4% in 2016–2017 (table 1). The number of CTCAs totalled 19 270 in 2011–2012 (30.5 tests per 100 000) but increased by 268% during the study period, peaking at 70 928 in 2016–2017 (108 tests per 100 000). The data normalised to those Trusts that supplied information (table 3) showed a similar pattern of increasing CTCA activity during the study period.

Regional inequalities in non-invasive test utilisation
ETT utilisation between 2011–2012 and 2016–2017 declined in English and Welsh Trusts by 15.8%, and 13.5%, respectively, but in Scottish Trusts ETT utilisation increased by 14.1% and in Northern Ireland Trusts, where ETT per 100000 population far exceeded rates elsewhere in the UK, its utilisation increased by 25.0% (see figure 3 and online supplementary file 1). Non-invasive imaging tests during the same period increased in English, Welsh and Northern Ireland Trusts by 85.1%, 115.7% and 50.7% but in Scottish Trusts the increase was only 3.9% (see figure 3 and online supplementary file 1), marking Scotland as the UK state performing the fewest non-invasive imaging tests.

Utilisation of CTCA showed the greatest increase in English and Welsh Trusts (281.4% and 290.0%) but in Scottish and Northern Ireland Trusts increases in CTCA utilisation were more modest (68.9% and 45.6%) and were dwarfed by increases in stress echo utilisation (172.9% and 291.1%). Stress cardiac stress/perfusion MRI (CMR) utilisation in all regions was relatively low but showed large increases during the study period (see figure 4, figure 5 and online supplementary file 1).

Invasive angiography and revascularisation
National registry data from the British Cardiovascular Interventional Society showed a 7.7% increase in diagnostic ICA during the study period, numbers increasing from 144 506 in 2011 to 155 777 in 2016 (figure 2). A similar 6.4% increase in percutaneous coronary intervention procedures for stable angina occurred during the same period, numbers increasing from 30 526 in 2011 to 32 475 in 2016. Elective isolated coronary bypass operations recorded in the Society for Cardiothoracic Surgery registry declined by 17.5% during the study period, from 10 671 in 2011 to 8804 in 2015 (most recent available data).

DISCUSSION
This study reports the utilisation of non-invasive functional and anatomical tests by hospital Trusts across the UK. Temporal trends during a 6-year period from 2011–2012 to 2016–2017 show that utilisation of all non-invasive imaging tests has increased substantially while utilisation of exercise treadmill tests has tended to slowly decline. Trends in test utilisation during the study period showed important regional differences, with Scottish and Northern Irish Trusts reporting little change in utilisation of non-invasive imaging tests.

In the 2010 NICE guideline ETT was no longer recommended to be used to diagnose or exclude stable angina. This recommendation, based largely on the inferior diagnostic performance of the ETT compared with non-invasive imaging tests, has been validated by investigators who have reported that its diagnostic and prognostic supplied information (table 3) showed a similar pattern of increasing CTCA activity during the study period.
value in patients with suspected angina is limited.\textsuperscript{9,10} In patients with established coronary artery disease, the ETT competes with a range of clinical factors for prognostic assessment and has either not been considered\textsuperscript{11,12} or has failed inclusion\textsuperscript{13} in the development of risk models. This study does not identify indications for non-invasive testing and as such the authors are cautious of drawing firm conclusions on the utilisation of ETT. Certainly, the changes in the 2010 NICE guidelines do not appear to have led to a significant drop in ETT use. Multiple factors are likely responsible for the continuing popularity of the ETT including its low cost, wide availability and status as a test that has been part of cardiological practice for more than 70 years. The superior diagnostic performance and cost-effectiveness of non-invasive imaging tests are well established\textsuperscript{14} and persistently high level of utilisation of ETTs may provide cause for concern if indeed they are being used for assessment of coronary artery disease. This is reflected in the many patients attending chest pain clinics who have a normal ETT but then go on to experience coronary events during follow-up.\textsuperscript{15} Notably trusts with the highest ETT.

The modest decline in the utilisation of ETTs by UK hospital Trusts during the study period was accompanied by a sharp increase in the utilisation of non-invasive imaging tests. By 2012–2013 numbers of non-invasive imaging tests had exceeded numbers of ETTs and the gap in utilisation continued to increase thereafter with MPS the most commonly employed modality. Utilisation of all other non-invasive imaging tests also increased, particularly CTCA, presumably reflecting its introduction as a clinical tool in NICE 2010 guideline recommendation for low risk patients, which has now been extended in the 2016 update.\textsuperscript{13} However, only 74% of UK Trusts reported utilisation of CTCA in 2016–2017, validating concerns about the implementation of NICE recommendations.\textsuperscript{16,17} Regional inequalities in resources appear to remain a challenge with Scotland and Northern Ireland showing only modest increases in CTCA utilisation during the study period despite performing as many if not more scans proportional to population in 2011–2012 compared with England and Wales. By contrast England and Wales have expanded CTCA services more vigorously, by 302% and 290%, respectively, particularly in South of England and North Wales. However, Wales still lags behind other UK nations in its overall utilisation of CTCA.

The while the increase in utilisation of CTCA is likely to be related in part to NICE 2010 guidelines during the study period it is unclear, however, what effect this guideline has had on the use of functional imaging during the study period. The use of functional imaging often expands beyond use in chest pain clinics and not infrequently in patients with established coronary artery disease, previously revascularised patients or even acute coronary syndromes. What has driven increasing use of these functional tests is not evident from this study. The data does show that, within the functional imaging modalities, use of stress echocardiography and CMR stress perfusion is increasing, while use of MPS remains high but has stalled somewhat in growth. This is reflected in growing number of centres reporting use stress echo and CMR stress compared with a steady state of centres offering MPS.

This study also gives scale and proportion to utilisation of both anatomical (CTCA) and functional imaging in the UK. In 2016–2017, 30% of all non-invasive tests were CTCA with 70% being functional imaging. This balance has shifted from the beginning of the study when CTCA contributed just 15% of all non-invasive tests. Certainly, the high use of functional imaging across UK Trusts during the study period is consistent with the US experience,\textsuperscript{18–20} where concerns have been expressed about

### Table 3

Mean test utilisation in UK National Health Service trusts between 2011–2012 and 2016–2017

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CTCA—total</td>
<td>19270</td>
<td>27388</td>
<td>36132</td>
<td>42405</td>
<td>48643</td>
<td>70928</td>
</tr>
<tr>
<td>Per 100 000 population</td>
<td>30.5</td>
<td>43.0</td>
<td>56.4</td>
<td>65.6</td>
<td>74.7</td>
<td>108.0</td>
</tr>
<tr>
<td>SE—total</td>
<td>35338</td>
<td>41861</td>
<td>46859</td>
<td>51999</td>
<td>57146</td>
<td>61458</td>
</tr>
<tr>
<td>Per 100 000 population</td>
<td>55.9</td>
<td>65.7</td>
<td>73.1</td>
<td>80.5</td>
<td>87.8</td>
<td>93.6</td>
</tr>
<tr>
<td>CMR—total</td>
<td>6109</td>
<td>7948</td>
<td>10408</td>
<td>11885</td>
<td>13857</td>
<td>15634</td>
</tr>
<tr>
<td>Per 100 000 population</td>
<td>9.7</td>
<td>12.5</td>
<td>16.2</td>
<td>18.4</td>
<td>21.3</td>
<td>23.8</td>
</tr>
<tr>
<td>MPS—total</td>
<td>69463</td>
<td>76301</td>
<td>88514</td>
<td>89224</td>
<td>87776</td>
<td>87427</td>
</tr>
<tr>
<td>Per 100 000 population</td>
<td>109.9</td>
<td>119.8</td>
<td>138.1</td>
<td>138.1</td>
<td>134.8</td>
<td>133.2</td>
</tr>
<tr>
<td>ETT—total</td>
<td>136030</td>
<td>134012</td>
<td>135420</td>
<td>133116</td>
<td>127986</td>
<td>124647</td>
</tr>
<tr>
<td>Per 100 000 population</td>
<td>215.3</td>
<td>210.4</td>
<td>211.2</td>
<td>206.1</td>
<td>196.6</td>
<td>189.9</td>
</tr>
<tr>
<td>All non-invasive imaging—total</td>
<td>130180</td>
<td>153498</td>
<td>181913</td>
<td>195513</td>
<td>207422</td>
<td>235447</td>
</tr>
<tr>
<td>Per 100 000 population</td>
<td>206.0</td>
<td>241.0</td>
<td>283.8</td>
<td>302.7</td>
<td>318.6</td>
<td>358.7</td>
</tr>
</tbody>
</table>

Data are the mean number of tests performed each year by trusts that responded to the Freedom of Information requests.

CMR, cardiac stress/perfusion MRI; CTCA, CT coronary angiography; ETT, exercise treadmill testing; MPS, myocardial perfusion scintigraphy; SE, stress echocardiography.
inappropriate indications and low diagnostic yield in terms of angiographic coronary artery disease. Importantly there is no evidence that high use of functional testing in US centres has driven improvements in outcomes. Conversely the SCOTHEART trial has recently provided some evidence that anatomical imaging may improve prognosis, although in comparison to ETT testing.

The increase in diagnostic testing that has occurred during the study period has been accompanied with only small changes in numbers of ICA and PCI procedures across the UK. This is a surprising response to the additional 105,267 non-invasive tests and in particular >50,000 additional CTCAs being performed per year that might be expected to have reduced the need for downstream invasive investigation. Equally conversion rates of ICA to PCI have remained static at around 40% with no apparent improvement in the diagnostic yield of obstructive coronary disease. There may be multiple explanations for this trend that cannot be described within this dataset alone.

Two key drivers though are likely to be responsible for this.

First, the individual weakness of each non-invasive test may belie the answer to the static conversion rates...
of ICA to PCI. Sensitivities and specificities of each non-invasive tests vary with CTCA having high specificity but reduced specificity for obstructive CAD, while functional imaging often has good specificity but lacks sensitivity for detecting CAD. This often leads clinicians with a choice of either ordering further tests or referring on for ICA as a final diagnostic test, even if this does not lead to revascularisation. Similar trends have been observed in the USA where increasing rates of invasive management have been recorded due to inappropriate or inaccurate testing. The 2010 NICE guideline also included the recommendation of ICA for all patients with a risk score >61% which may have contributed to greater utility of ICA despite the score overestimating risk of CAD.

Second, increased availability of testing demonstrated by this data does not mean these tests are being utilised appropriately as per guideline recommendations. In fact, the persistently high use of ETT even in 2016–2017 should be seen as a strong indicator that clinicians are quite happy to deviate from guidelines. It could therefore be assumed that the same is being done with regards non-invasive imaging and ICA. No national audit database exists linking non-invasive cardiac testing with downstream management. As such appropriateness of testing is unknown and cost analysis difficult to achieve. This study underlines the importance of prospective national auditing of non-invasive testing in order to achieve the cost savings predicted by NICE.

Although the data reported in this study are novel and nationally relevant three important limitations that need to be acknowledged. First, although the response rate to FOI requests was high it was incomplete with the data yield increasing from 81.9% in 2011–2012% to 92.1% in 2016–2017. The numbers of tests performed across the UK will therefore have been underestimated with some distortion of regional distribution although conclusions about the increasing use of anatomical and functional testing are unaffected. Second, data obtained from the FOI requests is dependent in part on the methods Trusts use in its collection. Most Trusts use coded data for recording diagnostic test utilisation but some extract numbers directly from cardiology or radiology department records. However, it is reassuring that FOI utilisation data for CTCA are very similar to previous 2015–2016 estimates using a different methodology and local validation at the authors centre appears accurate. Third, the indications or origin of requests for testing were not available for analysis and data from tests is not linked to the British Cardiovascular Intervention Society (BCIS) or the Society for Cardiothoracic Surgery (SCST) registries. As such this limits the conclusions that can be drawn on current practice.

This study has documented for the first time the utilisation of non-invasive testing modalities in Trusts across the UK. Numbers of non-invasive imaging tests have increased substantially with only a small decline in ETTs. The steep increase in utilisation of CTCA may reflect increasing guideline recommendations. Action is now required to reduce regional inequalities and determine appropriate-ness of cardiac testing in order to take advantage of the diagnostic value and the financial savings predicted by NICE. The extent to which the increasing rate of imaging in the UK is clinically appropriate requires further review.

Contributors AA, RG and GT collected and analysed the data. AA drafted the manuscript. AW, KR, DJ provided critical analysis and helped re-draft the manuscript. AT edited the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Map disclaimer The depiction of boundaries on the map(s) in this article do not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. The map(s) are provided without any warranty of any kind, either express or implied.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Alex Asher http://orcid.org/0000-0003-2110-3001

REFERENCES


